Cortexyme's phase 2/3 gain trial of atuzaginstat (cor388) in patients with alzheimer's disease successfully advances past interim analysis

South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx), a clinical stage biopharmaceutical company pioneering potential therapeutics for alzheimer's and other degenerative diseases, today announced that the independent data monitoring committee (dmc) conducted a pre-planned interim analysis and recommended cortexyme continue the phase 2/3 gain trial of atuzaginstat (cor388) as planned to the 1-year endpoint.  the interim analysis included approximately 300 patients who hav
QNCX Ratings Summary
QNCX Quant Ranking